Article info

Download PDFPDF
Gemcitabine–carboplatin–paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

Authors

  • L. Fuso Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit, Leuven, Belgium PubMed articlesGoogle scholar articles
  • F. Amant Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit, Leuven, Belgium PubMed articlesGoogle scholar articles
  • P. Neven Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit, Leuven, Belgium PubMed articlesGoogle scholar articles
  • P. Berteloot Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit, Leuven, Belgium PubMed articlesGoogle scholar articles
  • I. Vergote Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Katholieke Universiteit, Leuven, Belgium PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to: Prof. Ignace Vergote, MD, PhD, Division of Gynecologic Oncology, Department of Gynecologic Oncology, University Hospitals Leuven, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Email: ignace.vergote{at}uz.kuleuven.ac.be

Citation

Fuso L, Amant F, Neven P, et al
Gemcitabine–carboplatin–paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

Publication history

  • First published January 1, 2006.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.